See more : Nippon Sharyo, Ltd. (7102.T) Income Statement Analysis – Financial Results
Complete financial analysis of Abeona Therapeutics Inc. (ABEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abeona Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Norditek Group AB (publ) (NOTEK.ST) Income Statement Analysis – Financial Results
- Nova Royalty Corp. (NOVRF) Income Statement Analysis – Financial Results
- Albion Venture Capital Trust PLC (AAVC.L) Income Statement Analysis – Financial Results
- CanaFarma Hemp Products Corp. (CNFA.CN) Income Statement Analysis – Financial Results
- AppTech Payments Corp. (APCX) Income Statement Analysis – Financial Results
Abeona Therapeutics Inc. (ABEO)
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.50M | 1.41M | 3.00M | 10.00M | 0.00 | 3.00M | 837.00K | 889.00K | 1.04M | 925.00K | 2.04M | 4.40M | 1.85M | 481.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 549.00K | 1.30M | 1.15M | 243.00K | 107.00K | 15.00K | 100.00K | 435.00K | 167.00K | 2.95M |
| Cost of Revenue | 1.61M | 450.00K | 4.46M | 30.14M | 8.68M | 38.70M | 16.99M | 10.66M | 0.00 | 0.00 | 125.00K | 267.00K | 1.22M | 140.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 239.00K | 277.00K | 107.00K | 0.00 | 0.00 | 0.00 | 0.00 | 580.00K | 8.31M | 0.00 |
| Gross Profit | 1.90M | 964.00K | -1.46M | -20.14M | -8.68M | -35.70M | -16.15M | -9.77M | 1.04M | 925.00K | 1.92M | 4.14M | 632.00K | 341.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 310.00K | 1.02M | 1.04M | 243.00K | 107.00K | 15.00K | 100.00K | -145.00K | -8.15M | 2.95M |
| Gross Profit Ratio | 54.14% | 68.18% | -48.80% | -201.39% | 0.00% | -1,190.79% | -1,929.75% | -1,098.54% | 100.00% | 100.00% | 93.88% | 93.94% | 34.20% | 70.89% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 56.47% | 78.61% | 90.67% | 100.00% | 100.00% | 100.00% | 100.00% | -33.33% | -4,878.44% | 100.00% |
| Research & Development | 31.09M | 28.97M | 34.33M | 30.14M | 48.57M | 38.70M | 16.99M | 10.66M | 4.72M | 333.00K | 884.00K | 2.01M | 4.20M | 3.35M | 2.66M | 12.61M | 2.60M | 2.05M | 2.78M | 5.42M | 6.10M | 7.02M | 4.17M | 4.01M | 1.61M | 1.80M | 2.43M | 1.41M | 1.25M |
| General & Administrative | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 0.00 | 6.02M | 583.00K | 4.51M | 7.11M | 4.34M | 957.00K | 0.00 | 4.64B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.49M | 0.00 | 0.00 | 0.00 | 3.12M | 0.00 | -4.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 4.83M | 6.02M | 4.08M | 4.51M | 7.11M | 4.34M | 4.08M | 2.81M | 4.64M | 3.20M | 2.51M | 2.28M | 1.96M | 1.74M | 1.47M | 1.50M | 1.78M | 1.94M | 1.35M |
| Other Expenses | 0.00 | 141.00K | 3.25M | 4.59M | 7.82M | 2.36M | 741.00K | 825.00K | 551.00K | 3.72M | 4.84M | 419.00K | 4.31M | 238.00K | 259.00K | 253.00K | 4.36M | 3.12M | 6.84M | 3.97M | 3.14M | 2.72M | 2.38M | 2.16M | 1.76M | 1.70M | 1.95M | 2.06M | 1.35M |
| Operating Expenses | 49.03M | 46.22M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.72M | 8.45M | 8.51M | 8.10M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.39M | 9.23M | 9.74M | 6.55M | 6.17M | 3.36M | 3.50M | 4.38M | 3.47M | 2.60M |
| Cost & Expenses | 50.64M | 46.67M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.85M | 8.72M | 9.72M | 8.24M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.63M | 9.51M | 9.85M | 6.55M | 6.17M | 3.36M | 3.50M | 4.96M | 11.78M | 2.60M |
| Interest Income | 2.12M | 431.00K | 69.00K | 1.30M | 1.21M | 1.51M | 525.00K | 2.01M | 4.03M | 45.00K | 251.00K | 242.00K | 1.33M | 2.05M | 29.00K | 178.00K | 125.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 418.00K | 736.00K | 3.67M | 4.12M | 400.00K | 11.00K | 8.00K | 6.00K | 6.00K | 582.00K | 279.00K | 608.00K | 963.00K | 607.00K | 539.00K | 478.00K | 3.51M | 7.44M | 2.10M | 1.39M | 1.28M | 1.28M | 1.17M | 342.00K | 0.00 | 0.00 | 0.00 | 45.00K | 0.00 |
| Depreciation & Amortization | 3.20M | 4.58M | 4.46M | 5.60M | 8.68M | 2.36M | 741.00K | 825.00K | 551.00K | 11.00K | 3.00K | 419.00K | 233.00K | 238.00K | 259.00K | 253.00K | 2.60M | 7.06M | 1.57M | 1.08M | 898.00K | 686.00K | 627.00K | 476.00K | 285.00K | 200.00K | 162.00K | 123.00K | 15.00K |
| EBITDA | -50.57M | -34.38M | -76.80M | -74.52M | -67.61M | -54.31M | -26.58M | -21.05M | -13.97M | -26.19M | 4.73M | -9.51M | -1.32M | -6.69M | -16.54M | -16.48M | -18.12M | 2.99M | -7.56M | -4.93M | -4.53M | -8.01M | -5.68M | -5.58M | -3.06M | -3.30M | -4.36M | -11.49M | 356.00K |
| EBITDA Ratio | -1,444.91% | -3,160.18% | -1,801.70% | -426.17% | 0.00% | -1,811.21% | -3,174.43% | -2,366.93% | -1,343.17% | -332.43% | -173.85% | -82.99% | -341.40% | -1,309.77% | -642.90% | -5,664.60% | 12,847.37% | 0.00% | 0.00% | -1,457.74% | -564.86% | -698.69% | -2,337.86% | -5,216.82% | -20,426.67% | -3,200.00% | -1,030.11% | -6,997.60% | 12.09% |
| Operating Income | -47.14M | -45.26M | -89.84M | -81.42M | -77.09M | -58.17M | -27.84M | -23.88M | -18.55M | -3.13M | -3.80M | -4.32M | -7.88M | -7.76M | -9.68M | -16.92M | -6.90M | -5.18M | -9.62M | -9.08M | -8.21M | -8.70M | -6.31M | -6.06M | -3.35M | -3.40M | -4.52M | -11.61M | 341.00K |
| Operating Income Ratio | -1,346.71% | -3,200.64% | -2,994.53% | -814.20% | 0.00% | -1,940.16% | -3,325.69% | -2,686.28% | -1,783.27% | -338.49% | -186.29% | -98.00% | -426.19% | -1,612.68% | -2,748.86% | -5,812.71% | -12,105.26% | 0.00% | 0.00% | -1,653.73% | -634.21% | -758.50% | -2,595.88% | -5,661.68% | -22,326.67% | -3,400.00% | -1,040.00% | -6,953.89% | 11.58% |
| Total Other Income/Expenses | -7.05M | 11.22M | 4.90M | -2.81M | 808.00K | 1.50M | 517.00K | 2.01M | 4.02M | -23.65M | 8.25M | -6.22M | 5.36M | 220.00K | -7.15M | -300.00K | -15.02M | -8.25M | -4.07M | -1.16M | 1.79M | -684.00K | 281.00K | 630.00K | 41.00K | 0.00 | 83.00K | 151.00K | 0.00 |
| Income Before Tax | -54.19M | -39.70M | -84.94M | -84.23M | -76.28M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.52M | -8.98M | -16.83M | -17.22M | -21.92M | 13.42M | -11.62M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | 0.00 | -4.44M | -11.46M | 341.00K |
| Income Before Tax Ratio | -1,548.23% | -2,807.36% | -2,831.20% | -842.34% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -136.09% | -1,866.11% | -4,781.25% | -5,915.81% | -38,450.88% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | 0.00% | -1,020.92% | -6,863.47% | 11.58% |
| Income Tax Expense | 0.00 | -7.89M | 3.67M | 4.12M | 400.00K | 1.51M | 525.00K | 2.01M | 4.03M | 582.00K | 279.00K | 608.00K | 17.00K | -220.00K | 7.66M | 178.00K | -61.00K | -173.00K | -4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -83.00K | -151.00K | 0.00 |
| Net Income | -54.19M | -31.81M | -88.61M | -88.35M | -76.68M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.53M | -7.54M | -17.34M | -17.22M | -21.86M | -12.87M | -1.70M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | -3.40M | -4.44M | -11.46M | 341.00K |
| Net Income Ratio | -1,548.23% | -2,249.58% | -2,953.53% | -883.49% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -137.01% | -1,566.94% | -4,926.14% | -5,915.81% | -38,343.86% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | -3,400.00% | -1,020.92% | -6,863.47% | 11.58% |
| EPS | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.75 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| EPS Diluted | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.00 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| Weighted Avg Shares Out | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.19K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
| Weighted Avg Shares Out (Dil) | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.38K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates
NEW YORK and CLEVELAND, Ohio, May 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced the presentation of new preclinical data on AAV204 at the Association for Research and...
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on AAV204, a novel adeno-associated virus (AAV) capsid from Abeona's in-licensed AIM™...
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock
NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase...
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained FDA alignment on CMC requirements for EB-101 including characterization and validation plans
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
NEW YORK and CLEVELAND, March 28, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics, will participate in a panel...
Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEB
Topline data from VIITAL™ expected in the third quarter of 2022 Topline data from VIITAL™ expected in the third quarter of 2022
Abeona Therapeutics Issues Letter to Shareholders
NEW YORK and CLEVELAND, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to shareholders.
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
NEW YORK and CLEVELAND, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its underwritten public offering of 44,700,000 shares of its common stock and...
Abeona Therapeutics Stock (ABEO): Why The Price Fell Today
The stock price of Abeona Therapeutics Inc (NASDAQ: ABEO) fell by over 25% pre-market today. This is why it happened.
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
NEW YORK and CLEVELAND, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and sell shares of its common stock and warrants to...
Source: https://incomestatements.info
Category: Stock Reports